Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.
Tempest Therapeutics has raised $2.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
Tempest Therapeutics's investors include New Enterprise Associates, Foresite Capital, Lilly Asia Ventures, Versant Ventures, Eight Roads Ventures.
Tempest Therapeutics is headquartered in San Francisco, United States.
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.
Tempest Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tempest Therapeutics — Funding & Investors." VCBacked, September 11, 2026, https://www.vcbacked.co/company/tempest-therapeutics. Accessed October 17, 2026.
VCBacked. (2026). Tempest Therapeutics — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/tempest-therapeutics
{{cite web |title=Tempest Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tempest-therapeutics |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated